CARGO Therapeutics, Inc. Common Stock (CRGX)
Largest Insider Buys in Sector
CRGX Stock Price History Chart
CRGX Stock Performance
About CARGO Therapeutics, Inc. Common Stock
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, …
Insider Activity of CARGO Therapeutics, Inc. Common Stock
Over the last 12 months, insiders at CARGO Therapeutics, Inc. Common Stock have bought $0 and sold $294,684 worth of CARGO Therapeutics, Inc. Common Stock stock.
On average, over the past 5 years, insiders at CARGO Therapeutics, Inc. Common Stock have bought $10M and sold $294,684 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 666,666 shares for transaction amount of $10M was made by PERCEPTIVE ADVISORS LLC (Former 10% Owner) on 2023‑11‑14.
List of Insider Buy and Sell Transactions, CARGO Therapeutics, Inc. Common Stock
| 2024-09-19 | Sale | President & CEO | 2,975 0.0089% | $25.03 | $74,457 | -25.44% | ||
| 2024-09-18 | Sale | President & CEO | 7,166 0.0215% | $25.09 | $179,775 | -22.71% | ||
| 2024-09-18 | Sale | Chief Financial Officer | 1,600 0.0048% | $25.28 | $40,452 | -22.71% | ||
| 2023-11-14 | Former 10% Owner | 666,666 1.1951% | $15.00 | $10M | +32.51% |
Insider Historical Profitability
| PERCEPTIVE ADVISORS LLC | Former 10% Owner | 2912835 6.3284% | $14.71 | 1 | 0 | +32.51% |